Halozyme Therapeutics, Inc. HALO
HALO Rating
HALO Rating Factors
HALO Company Overview
Halozyme Therapeutics, Inc. is a U.S.-based biotechnology company focused on developing and commercializing drug delivery technologies and specialty therapeutics. The company operates primarily within the biopharmaceutical and oncology sectors, with its core business centered on its proprietary ENHANZE drug delivery platform, which enables subcutaneous administration of injectable biologics and therapeutics that are traditionally delivered intravenously. Halozyme generates revenue through product sales, licensing agreements, royalties, and collaborative partnerships with large pharmaceutical companies.
The company’s principal revenue drivers include royalties and milestone payments tied to partnered products using the ENHANZE platform, as well as sales from proprietary products. Halozyme serves global pharmaceutical manufacturers, healthcare providers, and patients requiring biologic therapies across oncology, immunology, hematology, and rare disease indications. The company was founded in 1998 and evolved from an early-stage enzyme technology developer into a platform-focused biotechnology company through strategic licensing arrangements and commercialization partnerships with major global drugmakers.
HALO Income Statement
HALO Balance Sheet
HALO Price History
HALO Valuation
HALO Dividends and Shares
HALO Corporate Info
San Diego, CA 92130